Capricor Therapeutics price target lowered to $22 from $43 at Oppenheimer

Oppenheimer lowered the firm’s price target on Capricor Therapeutics (CAPR) to $22 from $43 and keeps an Outperform rating on the shares. Following Friday’s STAT article that reported further detail around last week’s removal of deramiocel’s lead FDA reviewers, Oppenheimer does not expect this candidate to be approved for Duchenne cardiomyopathy in its current cycle, the analyst tells investors in a research note.